OABI OmniAb, Inc.: Price-to-Projected Revenue Ratio

OmniAb Corp - graphic logo of issuer OABI

OmniAb, Inc. (OABI) attracts leading biologists and engineers through innovative SaaS solutions and stock options. Analyzing the chart on GURU.Markets, we find that the issuer's forward P/S has reached 17.80. A robust patent shield and unique platforms create an insurmountable barrier to entry for competitors. However, geopolitical tensions and logistics disruptions are hindering global tests, thereby reducing licensing payments.

OABI omniab.com: Market Cap to Projected Revenue in the range 04/28/2023 - 11/17/2026

Metric breakdowns and analytics for OmniAb, Inc. (OABI)

- market price and analyst price targets:
Summary company analytics:OmniAb Corp (OABI)
Product sample of OmniAb Inc

The forward P/S ratio determines the market value of an asset relative to expected revenue, allowing an investor to assess the extent of the premium paid for future cash flows. By analyzing the forward P/S based on forecasts, one can understand to what extent the market prices in the success of OmniAb, Inc. (OABI) and its unique bio-factories for creating human antibodies, which radically accelerate the development of anti-cancer drugs for the largest pharmaceutical behemoths.